Compare DLHC & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLHC | ATYR |
|---|---|---|
| Founded | 1969 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.8M | 69.2M |
| IPO Year | N/A | 2015 |
| Metric | DLHC | ATYR |
|---|---|---|
| Price | $5.52 | $0.88 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 9.3K | ★ 2.5M |
| Earning Date | 02-09-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $322,607,000.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.81 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $0.64 |
| 52 Week High | $8.10 | $7.29 |
| Indicator | DLHC | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 38.00 | 54.93 |
| Support Level | $5.71 | $0.82 |
| Resistance Level | $6.13 | $0.94 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 0.00 | 54.37 |
DLH Holdings Corp delivers health and readiness solutions for federal government customers through digital transformation and cyber security, science research and development, and systems engineering and integration. It provides technology-enabled business process, program management, and digital transformation solutions to U.S. government agencies, focusing on large-scale, technology-powered health and defense initiatives for agencies including HHS, VA, DoD, and their sub-agencies. Its revenues come from technology-enabled business process outsourcing, program management solutions, and public health research and analytics under time-and-materials, cost-reimbursable, and firm-fixed-price contracts.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.